Targovax, a clinical stage company focused on developing immuno-oncology therapies to target solid tumours, appointed Michael Bogenstaetter as the company’s Chief Business Officer (CBO).
He will take up this role in January 2018.
Bogenstaetter joins Targovax following 25 years’ experience in biotech and big pharma.
During this time he held senior business development and strategy positions with Sanofi, Novartis and MDS.
Bogenstaetter has also worked as a consultant with The Boston Consulting Group and most recently, has acted as an independent corporate and business development advisor to some of the world’s top pharmaceutical and biotechnology companies.
He trained as a chemist and was awarded a PhD in organic chemistry from the University of Munich. Bogenstaetter also holds an MBA from London Business School.
Øystein Soug, CEO of Targovax, said: “We are delighted to announce the appointment of Michael as our Chief Business Officer. His extensive experience of business development and corporate strategy in the biotech and pharma industry will be indispensable to us.”
“2018 is set to be another important year for the company, containing a number of significant milestones for our pipeline of novel immuno-oncology therapies targeting treatment-resistant solid tumours.”
